June 29, 2017 / 1:10 PM / 2 months ago

BRIEF-Bayer enrolling patients into a global pulmonary arterial hypertension study

June 29 (Reuters) - Bayer AG

* Bayer- ‍Has enrolled first patient in a global phase IV study assessing clinical effects of riociguat in patients with pulmonary arterial hypertension​

* Bayer- ‍Study, which is part of collaboration between co, Merck, is seeking to enroll patients at 26 sites in U.S. with total of 100 study sites worldwide​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below